ICON  Overview
ICON  Mission and Vision
ICON  NoroBio Standard
ICON  Our Culture/Values
ICON  Drug Registration
ICON  Marketing & promotion
ICON  GO & NGO Tender
ICON Finished Medicine
ICON Medical Products
ICON Food supplement
ICON Excipient
ICON Packing Material
ICON  Meet us in CPHI
Betterway
English |  Français  |   Email
SWITCH TO VETERINARY
Home > Products > Finished Medicine > Injections
   - Finished Medicine
  - Tablets & Capsules
  - Powder for injection
  - Others
  - Injections
  - Bio Products
   + Medical Products
   + Food supplement
   + Excipient
   + Packing Material
 
 
 Hyoscine N-butylbromide (20mg/ml solution for injection)  
 

PHARMACOLOGICAL ACTION:
Hyoscine Butylbromide is a quaternary ammonium antimuscarinic agent. Hyoscine butylbromide does not readily pass the blood-brain barrier. It’s a competitive antagonist of the actions of acetylcholine and other muscarinic agonists. The receptors affected are those of peripheral structures that are either stimulated or inhibited by muscarine, ie. exocrine glands, smooth and cardiac muscle.

INDICATIONS:
Hyoscine Butylbromide is used in the treatment of conditions associated with gastro-intestinal spasm.

CONTRA-INDICATIONS:
Hypersensitivity to hyoscine butylbromide. Porphyria. Myasthenia gravis.
Patients with prostatic enlargement, paralytic ileus or pyloric stenosis and fever. In those with ulcerative colitis its use may lead to ileus or megacolon, and its effects on the lower oesophageal sphincter may exacerbate reflux. Closed angle glaucoma, or narrow angle between the iris and cornea, as hyoscine increases intra-ocular pressure. It should not given to patients with myasthenia gravis, unless it is to reduce the adverse muscarinic effects of an anti-cholinesterase agents.
It should not be given to pregnant and lactating mothers as safety has not been established. It has been stated to cross the placenta.

WARNINGS:
Patients who experience drowsiness should not drive or operate machinery. Alcohol should be avoided.

DOSAGE AND DIRECTIONS FOR USE:
The usual dose for adults and children over 12 years of age is 20 mg intramuscular or intravenous, repeated after 30 minutes, if necessary.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Dryness of the mouth, with difficulty in swallowing, thirst, dilation of the pupils with loss of accommodation and photophobia, increased intra-ocular pressure, flushing and dryness of the skin, bradycardia followed by tachycardia, with palpitations and arrhythmias, urinary urgency with the inability to do so, as well as reduction in the tone and motility of the gastro-intestinal tract, leading to constipation. Occasionally vomiting, giddiness and staggering may occur. Restrosternal pain may occur due to increased gastric reflux.
It has been stated that in elderly patients and patients with impaired metabolic, liver or kidney function, adverse central nervous system effects such as disorientation, delirium, or somnolence have been likely to occur.
It should be used with caution in conditions characterised by tachycardia such thyrotoxicosis, cardiac insufficiency or failure, and in cardiac surgery, where it may further accelerate the heart-rate. Care is required in patients with acute myocardial infarcation as ischaemia and infarcation may be worsened. It should be given with care to patients with hypertension.
Hyoscine should be used with care in patients receiving other central depressants, as central nervous system depression may be enhanced.
The effects of antimuscarinic agents may be enhanced by medicines with antimuscarinic properties, such as amantadine, some antihistamines, butyrophenones and phenothiazines, and tricyclic antidepressants.
It should be given with caution to patients with diarrhoea.
It should be used with caution in children and in geriatric patients, who may be more susceptible to its adverse effects.

© 2010 Noro Bio-Pharmaceutical Co., Ltd. all rights reservedExport Company